300142.SZ深圳证券交易所 · 创业板 ChiNext
Walvax Biotechnology 沃森生物
Biologics 生物制品
¥13.58−¥0.50 · −3.55%
Open 开盘
¥13.98
High 最高
¥14.06
Low 最低
¥13.56
Prev Close 昨收
¥14.08
Volume 成交量
8,793.1万股
Turnover 成交额
¥12亿
Mkt Cap 总市值
¥217亿
P/E 市盈率
115.0×
Recent Activity 近期动态All Filings 全部公告 →
26 significant filings since 30 May 2026: 22 on share issue, 1 on dividend and 3 on issue review inquiry. The latest, on 24 Sep 2026: 北京市竞天公诚律师事务所关于云南沃森生物技术股份有限公司2026年度向特定对象发行股票的补充法律意见书（二）.
自 30 May 2026 起有 26 份重大公告：share issue 22 份、dividend 1 份、issue review inquiry 3 份。最新一份（24 Sep 2026）：北京市竞天公诚律师事务所关于云南沃森生物技术股份有限公司2026年度向特定对象发行股票的补充法律意见书（二）。
11.0012.0013.0014.0015.0016.00
Volume 成交量
5.09亿
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Biologics 生物制品 · 58 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥217亿 | ¥107亿 | 11th highest of 58 · 58 家中第 11 高 | |
| Trailing P/E 市盈率 | 115.0x | 31.6x | 6th highest of 35 · 35 家中第 6 高 | |
| P/B 市净率 | 3.1x | 3.1x | 28th highest of 56 · 56 家中第 28 高 | |
| Revenue Growth 营收增速 | -27.7% | 2.5% | 6th lowest of 58 · 58 家中第 6 低 | |
| Profit Growth 净利增速 | 25.6% | 6.4% | 19th highest of 58 · 58 家中第 19 高 | |
| Gross Margin 毛利率 | 68.8% | 70.5% | 28th lowest of 58 · 58 家中第 28 低 | |
| Net Margin 净利率 | 5.5% | 8.9% | 25th lowest of 58 · 58 家中第 25 低 | |
| Return on Equity 净资产收益率 | 0.7% | 1.6% | 26th lowest of 57 · 57 家中第 26 低 | |
| Debt to Assets 资产负债率 | 30.2% | 24.1% | 24th highest of 58 · 58 家中第 24 高 | |
| Grade Score 评级得分 | 45 | 50 | 22nd lowest of 54 · 54 家中第 22 低 |
Statement figures are for the period to 30 Jun 2026, filed by 58 of 58 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，58 家同业中 58 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Biokin Pharmaceutical 百利天恒 | ¥988亿 | — | 21.4x | 9.4% | -874.0% | -28.9% | E |
| Remegen 荣昌生物 | ¥656亿 | 11.3x | 7.9x | 433.1% | 79.7% | 78.4% | A |
| Gan & Lee 甘李药业 | ¥439亿 | 38.2x | 3.7x | 7.6% | 27.4% | 5.2% | C |
| Junshi Biosciences 君实生物 | ¥358亿 | — | 6.0x | 45.2% | -2.4% | 0.4% | D |
| Sunshine Guojian Pharmaceutical 三生国健 | ¥351亿 | 11.4x | 4.1x | 34.8% | 42.5% | 4.3% | C |
| Shanghai RAAS Blood Products 上海莱士 | ¥331亿 | 27.4x | 1.0x | -18.8% | 20.6% | 2.0% | D |
| Chongqing Zhifei Biological Products 智飞生物 | ¥311亿 | — | 2.1x | -18.4% | -20.4% | -5.2% | D |
| Changchun High-Tech Industry 长春高新 | ¥289亿 | — | 1.3x | -16.1% | 7.9% | 2.1% | C |
| Hualan Biological Engineering 华兰生物 | ¥239亿 | 29.6x | 2.2x | -12.9% | 25.2% | 3.3% | C |
| Beijing Tiantan Biological Products 天坛生物 | ¥239亿 | 31.6x | 2.0x | -16.6% | 16.0% | 2.5% | D |
| Walvax Biotechnology 沃森生物 | ¥217亿 | 115.0x | 3.1x | -27.7% | 5.5% | 0.7% | D |
| Amoytop 特宝生物 | ¥210亿 | 19.4x | 6.8x | 21.6% | 25.9% | 13.2% | C |
| Acrobiosystems 百普赛斯 | ¥204亿 | 113.0x | 7.6x | 29.0% | 19.7% | 3.6% | B |
| Cansino Biologics 康希诺 | ¥202亿 | 496.1x | 4.1x | 43.8% | -0.1% | -0.0% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。